Noble Financial Cuts BioSig Technologies (NASDAQ:BSGM) Price Target to $2.00

BioSig Technologies (NASDAQ:BSGMGet Rating) had its price target dropped by research analysts at Noble Financial to $2.00 in a research note issued on Thursday, Stock Target Advisor reports. Noble Financial’s price objective indicates a potential upside of 392.25% from the stock’s previous close.

Separately, Taglich Brothers reaffirmed a “speculative buy” rating on shares of BioSig Technologies in a research note on Thursday, September 15th.

BioSig Technologies Price Performance

Shares of BioSig Technologies stock opened at $0.41 on Thursday. BioSig Technologies has a 12-month low of $0.25 and a 12-month high of $3.51. The company’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $0.76.

Insider Buying and Selling

In other BioSig Technologies news, insider Gray Fleming acquired 36,036 shares of the company’s stock in a transaction that occurred on Wednesday, August 24th. The shares were acquired at an average price of $1.18 per share, with a total value of $42,522.48. Following the completion of the purchase, the insider now directly owns 36,036 shares of the company’s stock, valued at approximately $42,522.48. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired 133,102 shares of company stock valued at $144,388 over the last quarter. Corporate insiders own 13.19% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. raised its holdings in BioSig Technologies by 6.7% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 345,807 shares of the company’s stock worth $228,000 after buying an additional 21,618 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in BioSig Technologies by 24.2% in the first quarter. Commonwealth Equity Services LLC now owns 125,705 shares of the company’s stock worth $144,000 after buying an additional 24,500 shares during the last quarter. Warberg Asset Management LLC purchased a new position in BioSig Technologies in the second quarter worth about $43,000. Advisor Group Holdings Inc. raised its holdings in BioSig Technologies by 394.9% in the first quarter. Advisor Group Holdings Inc. now owns 85,859 shares of the company’s stock worth $99,000 after buying an additional 68,509 shares during the last quarter. Finally, Truist Financial Corp purchased a new position in BioSig Technologies in the third quarter worth about $114,000. 9.46% of the stock is owned by hedge funds and other institutional investors.

BioSig Technologies Company Profile

(Get Rating)

BioSig Technologies, Inc, together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.

Featured Articles

Stock Target Advisor logo

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.